Search
Bolt Biotherapeutics Inc
BOLTAdd to Watchlist
4.050USD
+0.060+1.50%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
7.78MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.50%
5 Days
-5.27%
1 Month
-14.92%
6 Months
-30.05%
Year to Date
-25.93%
1 Year
-31.59%
Key Figures
4.080Open
4.135High
4.41KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.23%Turnover Ratio
3.990Prev. Close
4.050Low
12.96KTurnover
LossP/E Static
0.29P/B
0.00%Div Yield TTM
-44.19%ROA
7.35052wk High
0.24Volume Ratio
-63.12MNet Profit
1.92MShares
-16.4006EPS TTM
1.12Beta
-88.79%ROE
3.91052wk Low
2.13%Amplitude
100.00%Gross Margin
7.78MMarket Cap
-3.79Reward/Risk
4.26%Risk Rate
TradingKey Stock Score of Bolt Biotherapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Bolt Biotherapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 160 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bolt Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Bolt Biotherapeutics Inc Highlights
StrengthsRisks
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.70M.
Fairly Valued
The company’s latest PE is -0.25, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 516.47K shares, decreasing 49.40% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
29.000
Target Price
+626.82%
Upside Space
Bolt Biotherapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bolt Biotherapeutics Inc Info
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Ticker SymbolBOLT
CompanyBolt Biotherapeutics Inc
CEOQuinn (William P)
Websitehttps://boltbio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Bolt Biotherapeutics Inc (BOLT)?
The current price of Bolt Biotherapeutics Inc (BOLT) is 4.05.
What is the symbol of Bolt Biotherapeutics Inc?
The ticker symbol of Bolt Biotherapeutics Inc is BOLT.
What is the 52-week high of Bolt Biotherapeutics Inc?
The 52-week high of Bolt Biotherapeutics Inc is 7.35.
What is the 52-week low of Bolt Biotherapeutics Inc?
The 52-week low of Bolt Biotherapeutics Inc is 3.91.
What is the market capitalization of Bolt Biotherapeutics Inc?
The market capitalization of Bolt Biotherapeutics Inc is 7.78M.
Is Bolt Biotherapeutics Inc (BOLT) currently rated as Buy, Hold, or Sell?
According to analysts, Bolt Biotherapeutics Inc (BOLT) has an overall rating of Buy, with a price target of 29.00.
What is the Earnings Per Share (EPS TTM) of Bolt Biotherapeutics Inc (BOLT)?
The Earnings Per Share (EPS TTM) of Bolt Biotherapeutics Inc (BOLT) is -17.85.